Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status
Open Access
- 4 February 2014
- journal article
- research article
- Published by Springer Nature in Molecular Cancer
- Vol. 13 (1) , 21
Abstract
Cancer is the result of a multistep process of genomic alterations, including mutations in key regulatory proteins that result in loss of balanced gene expression and subsequent malignant transformation. Throughout the various stages of colorectal carcinoma (CRC), complex genetic alterations occur, of which over-expression of growth factors, such as vascular endothelial growth factor, fibroblast growth factor and platelet-derive growth factor and their corresponding receptor tyrosine kinases, have been shown to correlate with invasiveness, tumor angiogenesis, metastasis, recurrence, and poor prognosis of colorectal cancer. To evaluate the therapeutic effect, we combined Dovitinib, an orally bioavailable, potent inhibitor of class III-V receptor tyrosine kinases with chemotherapeutic drug, oxaliplatin in preclinical models of colon cancer.Keywords
This publication has 70 references indexed in Scilit:
- Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC PatientsChemotherapy Research and Practice, 2012
- Fibroblast Growth Factor Receptor 2: Expression, Roles, and Potential As a Novel Molecular Target for Colorectal CancerPathology Research International, 2012
- A systematic review of treatment guidelines for metastatic colorectal cancerColorectal Disease, 2011
- Accumulation of driver and passenger mutations during tumor progressionProceedings of the National Academy of Sciences, 2010
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- A multidimensional analysis of genes mutated in breast and colorectal cancersGenome Research, 2007
- Colorectal cancer: genetics of development and metastasisJournal of Gastroenterology, 2006
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Live or let die: the cell's response to p53Nature Reviews Cancer, 2002
- Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell deathOncogene, 2000